Skip to content
POM-V Prescription Required Companion Animal

UpCard 7.5 mg Tablets for Dogs

Active ingredient: Torasemide

Form

Tablet

Species

Dogs

Manufacturer

Vetoquinol SA

VMD MA No.

06462/5015

What it's used for

For treatment of clinical signs related to congestive heart failure in dogs, including pulmonary oedema.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Torasemide

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

UpCard 7.5 mg Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For treatment of clinical signs related to congestive heart failure in dogs, including
pulmonary oedema.
The veterinary medicinal product can be administered with or without food.
The recommended dose of torasemide is 0.1 to 0.6 mg/kg bodyweight, once
daily. The majority of dogs are stabilised at a dose of torasemide less than or
equal to 0.3 mg/kg bodyweight, once daily. The dosage should be titrated to
maintain patient comfort with attention to renal function and electrolyte status. If
the level of diuresis requires alteration, the dose may be increased or
decreased within the recommended dose range by increments of 0.1 mg/kg
bodyweight. Once signs of congestive heart failure have been controlled and
the patient is stable, if long term diuretic therapy with this product is required it
should be continued at the lowest effective dose.
Frequent re-examinations of the dog will enhance the establishment of an
appropriate diuretic dose.
The daily schedule of administration can be timed to control the period of
micturition according to need.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases of renal failure.

Revised February 2025
Do not use in cases of severe dehydration, hypovolaemia or hypotension.
Do not use concomitantly with other loop diuretics.
Dogs:
Very common
(>1 animal / 10
animals treated):
Elevated renal parameters, Renal
insufficiency
Haemoconcentration, Polyuria, Polydipsia
Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Hypokalaemia*
, Hypochloraemia*
,
Hypomagnesaemic condition *
Dehydration
Emesis, Constipation, Reduced faecal
output, Diarrhoea*
Pinnal erythema
*
1:
In cases of prolonged treatment
*
: Transient, mild, and does not necessitate the withdrawal of the treatment
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or the national
competent authority via the national reporting system. See the package leaflet
for respective contact details.
None

Special precautions for safe use in the target species:
In dogs presenting in acute crisis with pulmonary oedema, pleural effusion
and/or ascites requiring emergency treatment, the use of injectable drugs
should be considered first before commencing oral diuretic therapy.
Renal function, hydration status and serum electrolytes status should be
monitored:
-at treatment initiation
-from 24 hours to 48 hours after treatment initiation
-from 24 hours to 48 hours after dose change
-in case of adverse events.
While the animal is on treatment, these parameters should be monitored at very
regular intervals according to the benefit-risk assessment performed by the
responsible veterinarian (see sections 4.3 and 4.6 of the SPC).
Torasemide should be used with caution in cases of diabetes mellitus, and in
dogs with previously prescribed high doses of an alternative loop diuretic. In
dogs with pre-existing electrolyte and/or water imbalance, this should be
corrected prior to treatment with torasemide.
Torasemide treatment should not be initiated in dogs already clinically stable on
an alternative diuretic for treatment of the signs of congestive heart failure,
except where this has been justified taking into account the risk of de-stabilising
the clinical condition and of adverse reactions as indicated in section 4.6.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
People with known hypersensitivity to torasemide or other sulphonamides
should administer the veterinary medicinal product with caution.
This product may cause increased urination and/or gastrointestinal
disturbances if ingested.
Keep tablets in the blister packs until required, and keep the blisters in the outer
carton.
In case of accidental ingestion, particularly in the case of children, seek medical
advice immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable

Revised February 2025
Co-administration of loop diuretics and non-steroidal anti-inflammatory drugs
(NSAIDs) can result in a decreased natriuretic response.
Concomitant use with veterinary medicinal products affecting electrolyte
balance (corticosteroids, amphotericin B, cardiac glycosides, other diuretics)
requires careful monitoring.
Concurrent use of veterinary medicinal products that increase the risk of renal
injury or renal insufficiency should be avoided. Concomitant use with
aminoglycosides or cephalosporins may increase the risk of nephrotoxicity and
ototoxicity.
Torasemide may increase the risk of sulfonamide allergy.

Revised February 2025
Torasemide can reduce the renal excretion of salicylates, leading to an
increased risk of toxicity. Care should be exercised when administering
torasemide with other highly plasma protein-bound drugs.
Since protein binding facilitates the renal secretion of torasemide, a decrease in
binding due to displacement by another drug may be a cause of diuretic
resistance.
Concomitant administration of torasemide with other veterinary medicinal
products metabolised by cytochrome P450 isoforms such as 3A4 (e.g.:
enalapril, buprenorphine, doxycycline, cyclosporine) and 2E1 (isoflurane,
sevoflurane, theophylline) may decrease their clearance from the systemic
circulation.
The effect of antihypertensive medicinal products, especially angiotensin-
converting enzyme (ACE) inhibitors, may be potentiated when co-administered
with torasemide.
When used in combination with cardiac treatments (e.g. ACE-inhibitors,
digoxin), the dose regimen may need to be modified depending upon the
animal’s response to therapy.
This veterinary medicinal product does not require any special storage
conditions.
Any part tablet should be stored in the blister pack or in a closed container for a
maximum of 7 days.
Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.